For US Healthcare Professionals
For US Healthcare Professionals
For US Healthcare Professionals
TREMFYA® EFFICACY DATA IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
EFFICACY DATA IN SUBPOPULATIONS
TREMFYA® Is Proven Effective in Difficult-to-Treat Scalp Psoriasis: More Than 4 Out of 5 Patients Were Rated as Cleared or Almost Cleared (ss-IGA 0/1) of Scalp Psoriasis at Week 161*
VOYAGE 1: ss-IGA 0/1, MAJOR SECONDARY ENDPOINT
†P<0.001 vs placebo.
Based on the results of an analysis of the 101 global sites from VOYAGE 1 (including North American sites [ie, United States and Canada]).
*In a subpopulation of patients with scalp-specific Investigator's Global Assessment (ss-IGA) score ≥2 at baseline, ss-IGA scores were assessed in terms of clinical signs of redness, thickness, and scaliness using a 5-point scale where overall lesions were rated as absence of disease (0), very mild (1), mild (2), moderate (3), or severe (4).
Reference: 1. Data on file. Janssen Biotech, Inc.
PASI 90 Response With TREMFYA® at Week 24 by Baseline Body Weight Quartile1*
POST HOC ANALYSIS: POOLED DATA FROM VOYAGE 1 AND VOYAGE 2—PASI 90 AT WEEK 24 (NORTH AMERICAN ANALYSIS)
Nonresponder imputation (NRI) methods were used.
This is a post hoc analysis; statistical significance has not been established.
TREMFYA® analysis is based on the pooled results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American sites (United States=31, Canada=10) from VOYAGE 2.
*The quartile cutoffs are based on the overall (global) population across the 2 pooled studies.
PASI 90 Response With TREMFYA® at Week 24 by Baseline BMI Category
POST HOC ANALYSIS: POOLED DATA FROM VOYAGE 1 AND VOYAGE 2—PASI 90 AT WEEK 24 (NORTH AMERICAN ANALYSIS)
Nonresponder imputation (NRI) methods were used.
This is a post hoc analysis; statistical significance has not been established.
TREMFYA® analysis is based on the pooled results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American sites (United States=31, Canada=10) from VOYAGE 2.
Reference: 1. Data on file. Janssen Biotech, Inc.
TREMFYA® Is Proven Effective in Difficult-to-Treat Scalp Psoriasis: More Than 4 Out of 5 Patients Were Rated as Cleared or Almost Cleared (ss-IGA 0/1) of Scalp Psoriasis at Week 161*
VOYAGE 1: ss-IGA 0/1, MAJOR SECONDARY ENDPOINT
Example of scalp psoriasis; not an actual TREMFYA® patient. Image is for illustrative purposes only and is used with permission from Janssen Biotech, Inc.
Based on the results of an analysis of the 101 global sites from VOYAGE 1 (including North American sites [ie, United States and Canada]).
*In a subpopulation of patients with scalp-specific Investigator's Global Assessment (ss-IGA) score ≥2 at baseline, ss-IGA scores were assessed in terms of clinical signs of redness, thickness, and scaliness using a 5-point scale where overall lesions were rated as absence of disease (0), very mild (1), mild (2), moderate (3), or severe (4).
Reference: 1. Data on file. Janssen Biotech, Inc.
PASI 90 Response With TREMFYA® at Week 24 by Baseline Body Weight Quartile1*
POST HOC ANALYSIS: POOLED DATA FROM VOYAGE 1 AND VOYAGE 2—PASI 90 AT WEEK 24 (NORTH AMERICAN ANALYSIS)
Nonresponder imputation (NRI) methods were used.
This is a post hoc analysis; statistical significance has not been established.
TREMFYA® analysis is based on the pooled results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American sites (United States=31, Canada=10) from VOYAGE 2.
*The quartile cutoffs are based on the overall (global) population across the 2 pooled studies.
PASI 90 Response With TREMFYA® at Week 24 by Baseline BMI Category
POST HOC ANALYSIS: POOLED DATA FROM VOYAGE 1 AND VOYAGE 2—PASI 90 AT WEEK 24 (NORTH AMERICAN ANALYSIS)
Nonresponder imputation (NRI) methods were used.
This is a post hoc analysis; statistical significance has not been established.
TREMFYA® analysis is based on the pooled results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American sites (United States=31, Canada=10) from VOYAGE 2.
Reference: 1. Data on file. Janssen Biotech, Inc.
